• Save €1.20
VOLTALGAN SKIN FOAM 3% 50G
search

VOLTALGAN SKIN FOAM 3% 50G

  • 037645013
Features:


Indicated for joint and muscle pain.


Indicated in case of contractures, neuralgia and arthrosis.


Deductible over-the-counter drug.


Analgesic and anti-inflammatory action.


















info_outline View product sheet
Final Price €13.70
Regular Price €14.90
Save €1.20
Quantity
check_circle Available (20 Items)
48h
  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service

Drugs Others products at unbeatable price

VOLTALGAN SKIN FOAM 3% 50G



































TECHNICAL SHEET RCP DRUGS FROM DATABASE







[su_spoiler title = "MEDICINAL NAME"style =" fancy "icon =" chevron-circle "]



VOLTALGAN 3% Skin foam



[/ su_spoiler]

[su_spoiler title = "QUALITATIVE AND QUANTITATIVE COMPOSITION"style =" fancy "icon =" chevron-circle "]



100 g of skin foam contain:

Diclofenac 3 g



[/ su_spoiler]



[su_spoiler title = "PHARMACEUTICAL FORM"style =" fancy "icon =" chevron-circle "]



Skin foam.



[/ su_spoiler]

[su_spoiler title = "THERAPEUTIC INDICATIONS"style =" fancy "icon =" chevron-circle "]



Local treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.



[/ su_spoiler]

[su_spoiler title = "DOSAGE AND METHOD OF ADMINISTRATION"style =" fancy "icon =" chevron-circle "]





Adults over 18 years: Apply VOLTALGAN skin foam 1-3 times a day or according to medical prescription. For each application, spray on the palm of the hand, depending on the size of the area to be treated, a circular mass of foam of 3-5 centimeters in diameter (equal to about 0.75-1.5 grams in weight), massaging gently until completely absorption. In case of iontophoresis treatment, the product must be applied to the negative pole. VOLTALGAN cutaneous foam can also be used in combination with ultrasound therapy.

After application, wash your hands, otherwise they will also be treated with the skin foam.

Warning: use only for short periods of treatment.

Teenagers from 14 to 18 years: Apply VOLTALGAN skin foam 1-3 times a day or according to medical prescription. For each application, spray on the palm of the hand, depending on the size of the area to be treated, a circular mass of foam of 3-5 centimeters in diameter (equal to about 0.75-1.5 grams in weight), massaging gently until completely absorption. In case of iontophoresis treatment, the product must be applied to the negative pole. VOLTALGAN cutaneous foam can also be used in combination with ultrasound therapy.

After application, wash your hands, otherwise they will also be treated with the skin foam.

If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult your doctor.

Children below 14 years: There are insufficient data on efficacy and safety in children and adolescents below 14 years.

Therefore the use of Voltalgan cutaneous foam is contraindicated in children under 14 years of age.

Elderly: The usual adult dosage may be used.

How to use: Shake before use. With the can upside down, dispense the desired quantity by pressing the appropriate dispenser.



[/ su_spoiler]





[su_spoiler title = "CONTRAINDICATIONS"style =" fancy "icon =" chevron-circle "]



Hypersensitivity to the active substance or to any of the excipients.

Patients who have experienced asthma attacks, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).

Third trimester of pregnancy.

Children and adolescents:

Use in children and adolescents under the age of 14 is contraindicated.

[/ su_spoiler]



[su_spoiler title = "WARNINGS AND PRECAUTIONS FOR USE"style =" fancy "icon =" chevron-circle "] The possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see summary of the product characteristics of the systemic forms of diclofenac).

Topical diclofenac should only be applied to intact, non-diseased skin, and not to skin wounds or open lesions. It should not be allowed to come into contact with eyes or mucous membranes and should not be ingested.

Discontinue treatment if skin rash develops after application of the product.

Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass.

The concomitant use of systemic anti-inflammatory drugs is not recommended in elderly and / or gastric patients. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp), react, with asthmatic attacks, local inflammation of the skin, mucosa (Quincke's edema) or urticaria, to antirheumatic treatment carried out with NSAIDs , more often than other patients. Keep this medicine out of the reach and sight of children. The administration of VOLTALGAN should be discontinued in women who have fertility problems or who are undergoing fertility investigations. The use of VOLTALGAN, especially if prolonged, can give rise to local sensitization phenomena, which require the interruption of treatment and the adoption of adequate therapeutic measures. To reduce any phenomena of photosensitization it is advisable not to expose yourself excessively to the sun during use. In case of allergic reactions or adverse reactions of greater importance, it is necessary to stop the therapy and consult the doctor. [/ Su_spoiler]



[su_spoiler title = "INTERACTIONS"style =" fancy "icon =" chevron-circle "]



Since the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.

However, the possibility of competition between absorbed diclofenac and other drugs with high plasma protein binding should be borne in mind in high-dose and prolonged treatments.



[/ su_spoiler]

[su_spoiler title = "FERTILITY, PREGNANCY AND BREASTFEEDING"style =" fancy "icon =" chevron-circle "]



Pregnancy

The systemic concentration of diclofenac compared with oral formulations is lower after topical administration. Referring to experience with NSAID treatment for systemic administration, the following is recommended:

Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased by less than 1%, up to about 1.5%. The risk was considered to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause increased pre- and post-implantation loss and embryo-fetal mortality.

Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered except in strictly necessary cases. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to:

cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension);

renal dysfunction, which can progress to renal failure with oligo-hydroamnios;

the mother and the newborn, at the end of pregnancy, to:

possible prolongation of bleeding time, and antiplatelet effect which may occur even at very low doses;

inhibition of uterine contractions resulting in delayed or prolonged labor.

Consequently, diclofenac is contraindicated during the third trimester of pregnancy.

Feeding time

Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at therapeutic doses of Voltalgan no effects on the infant are anticipated. Due to the lack of controlled studies in breastfeeding women, the product should only be used during breastfeeding under the advice of a healthcare professional. In this circumstance, Voltalgan should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for an extended period of time.



[/ su_spoiler]

[su_spoiler title = "EFFECTS ON THE ABILITY TO DRIVE VEHICLES"style =" fancy "icon =" chevron-circle "]



The cutaneous application of topical diclofenac has no or negligible influence on the ability to drive or use machines.



[/ su_spoiler]

[su_spoiler title = "SIDE EFFECTS"style =" fancy "icon =" chevron-circle "]





Adverse reactions are listed by frequency, most frequent first, using the following convention: common (≥1 / 100,



Disorders of the immune system


Very rare:


Hypersensitivity (including urticaria), angioneurotic edema


Infections and infestations


Very rare:


Rash with pustules


Respiratory, thoracic and mediastinal disorders


Very rare:


Asthma


Skin and subcutaneous tissue disorders


Common:


Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus


Rare:


Bullous dermatitis, burning


Very rare:


Photosensitivity reaction


The use of the medicine in combination with other medicines containing diclofenac can lead to skin reactions with severe evolution (Stevens-Johnson syndrome, Lyell syndrome).


Reporting of suspected adverse reactions


Reporting of suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit / risk ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system www.agenziafarmaco.gov.it/it/responsabili".


[/ su_spoiler]







[su_spoiler title = "OVERDOSE"style =" fancy "icon =" chevron-circle "]



The low systemic absorption of topical diclofenac makes an overdose very unlikely.

However, undesirable effects similar to those seen after an overdose of diclofenac tablets may be expected if topical diclofenac is inadvertently ingested (1 pressurized container of 50 g foam contains approximately 1.54 g diclofenac sodium). In the event of accidental ingestion resulting in significant systemic side effects, the general therapeutic measures normally taken to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Gastric decontamination and the use of activated charcoal must be considered, especially within a short time after ingestion. [/ Su_spoiler]



[su_spoiler title = "LIST OF EXCIPIENTS"style =" fancy "icon =" chevron-circle "]



Sodium hydroxide, Caprilocapric macrogolglycerides, Hydrogenated soy lecithin, Polysorbate 80, Benzyl alcohol, Potassium sorbate, Disodium phosphate dodecahydrate, All-rac-α-tocopheryl acetate, Mint / eucalyptus fragrance, Purified water.

Each pressurized container (50 g) contains: 47.5 g of solution and 2.5 g of propellant (isobutane; n-butane; propane).



[/ su_spoiler]





[su_spoiler title = "STORAGE"style =" fancy "icon =" chevron-circle "]



Store below 30 ° C Pressurized container: VOLTALGAN contains flammable propellant. Protect from sunlight and do not expose to temperatures exceeding 50 ° C. Keep away from any source of combustion.



[/ su_spoiler]









[su_spoiler title = "MARKETING AUTHORIZATION HOLDER"style =" fancy "icon =" chevron-circle "] GlaxoSmithKline Consumer Healthcare SpA Via Zambeletti snc Baranzate (MI)





[/ su_spoiler]

[su_spoiler title = "AUTHORIZATION NUMBER - MINSAN"style =" fancy "icon =" chevron-circle "]



AIC n. 037645013



[/ su_spoiler]





































037645013
20 Items